Ninety per cent of NSCLC EGFR mutations comprise a leucine to arginine substitution at position 858 in exon 21 (L858R) or various deletion mutations in exon 19 [19–23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.